Система VI-RADS и уровни биомаркеров опухолевого микроокружения у больных раком мочевого пузыря при выборе тактики лечения

Objective : to identify the role simultaneous use of the Vesical Imaging-Reporting and Data System (VI-RADS) and the assessment of serum levels of several mediators and growth factors for the evaluation of metastatic process and disease stage in patients with bladder cancer. Materials and methods . This retrospective study included 85 patients with histologically verified transitional cell (urothelial) bladder carcinoma (stages рТа—TINOMO. [)T2NOMO, рТ3—4NN0M0, and [)T2—4N1—3M1) and 20 healthy controls. In addition to general clinical examinations, all patients have undergone preoperative diffusion-weighted magnetic resonance imaging of the pelvis with background suppression. We calculated the diffusion coefficient and included it into the VI-RADS protocol. All study participants were also tested for their serum levels of vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MSP-1), interferon γ (IFN-γ), transforming growth factor β1 (TGF- β1), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colonystimulating factor (GM-CSF) using enzyme-linked immunosorbent assay (ELISA). Results and conclusion . We found that the preoperative use of VI-RADS together with the assessment of serum levels of pro-inflammatory mediators, colony-stimulating factors, and growth factors in patients with muscle-invasive bladder cancer provide additional information about the activity of malignant transformation in tumor tissue and tumor spread. Their simultaneous use during the examination of patients with muscle-invasive bladder cancer is a promising diagnostic approach to monitor treatment response.